Receipt of disease-modifying antirheumatic drugs among patients with rheumatoid arthritis in medicare managed care plans

JAMA

Volumn 305, Issue 5, 2011, Pages 480-486

  Gabriela, Schmajuk ^a   Trivedi, Amal N ^b   Solomon, Daniel H ^c   Yelin, Edward ^d   Trupin, Laura ^d   Chakravarty, Eliza F ^a   Yazdany, Jinoos ^d  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b BROWN UNIVERSITY   (United States)

^c HARVARD UNIVERSITY   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DISEASE MODIFYING ANTIRHEUMATIC DRUG;

AGE; AGED; ARTICLE; CONTROLLED STUDY; DEMOGRAPHY; FEMALE; GEOGRAPHY; HEALTH CARE DELIVERY; HUMAN; LOWEST INCOME GROUP; MAJOR CLINICAL STUDY; MALE; MEDICARE; NEGRO; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; SEX DIFFERENCE; SOCIOECONOMICS;

EID: 79551564550     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.2011.67     Document Type: Article

References (39)

1. American College of Rheumatology Subcommittee on Clinical Guidelines. Guidelines for the management of RA: 2002 update. Arthritis Rheum. 2002; 46:328.
2. Saag KG, Teng GG, Patkar NM, et al; American College of Rheumatology. American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis. Arthritis Rheum. 2008; 59(6):762-784.
3. Edwards CJ, Arden NK, Fisher D, et al. The changing use of disease-modifying anti-rheumatic drugs in individuals with rheumatoid arthritis from the United Kingdom General Practice Research Database. Rheumatology (Oxford). 2005;44(11):1394-1398.
4. Schmajuk G, Schneeweiss S, Katz JN, et al. Treatment of older adult patients diagnosed with rheumatoid arthritis. Arthritis Rheum. 2007;57(6):928-934.
5. Khanna R, Smith MJ. Utilization and costs of medical services and prescription medications for rheumatoid arthritis among recipients covered by a state Medicaid program. Clin Ther. 2007;29(11):2456-2467.
6. Grijalva CG, Chung CP, Stein CM, Mitchel EF Jr, Griffin MR. Changing patterns of medication use in patients with rheumatoid arthritis in a Medicaid population. Rheumatology (Oxford). 2008;47(7): 1061-1064.
7. Widdifield J, Bernatsky S, Paterson JM, Thorne JC, Cividino A, Pope J, Gunraj N, Bombardier C. Quality care in seniors with new-onset rheumatoid arthritis. Arthritis Care Res (Hoboken). 2011;63(1):53-57.
8. Trivedi AN, Zaslavsky AM, Schneider EC, Ayanian JZ. Trends in the quality of care and racial disparities in Medicare managed care. N Engl J Med. 2005; 353(7):692-700.
9. Health Care Financing Administration. Medicare HEDIS data audits: Medicare HEDIS 3.0/1998 data audit report. http://permanent.access.gpo.gov/ websites/www.hcfa.gov/quality/3i2.htm. Accessed August 2, 2010.
10. Koroukian SM, Dahman B, Copeland G, Bradley CJ. The utility of the state buy-in variable in the Medicare denominator file to identify dually eligible Medicare-Medicaid beneficiaries. Health Serv Res. 2010; 45(1):265-282.
11. Agency for Healthcare Research and Quality. Creation ofnewrace-ethnicity codesandsocioeconomic status (SES) indicators for Medicare beneficiaries: final report, AHRQpublication no. 08-0029-ef, January 2008. http://www.ahrq.gov/qual/ medicareindicators/. Accessed February 11, 2010.
12. Best AE. Secondary data bases and their use in outcomes research. J Med Syst. 1999;23(3):175-181.
13. The InterStudy Competitive Edge 12.1 [database]. St Paul, MN: InterStudy Publications; 2001.
14. Agency for Healthcare Research and Quality. Rheumatoid arthritis: percentage of members who were diagnosed with rheumatoid arthritis and who were dispensed at least one ambulatory prescription for a disease modifying anti-rheumatic drug (DMARD). http://qualitymeasures.ahrq.gov/content.aspx?id= 14957#Section304. Accessed January 11, 2011.
15. Sequist TD, Schneider EC. Addressing racial and ethnic disparities in health care. Health Serv Res. 2006; 41(4 pt 1):1451-1468.
16. Arday SL, Arday DR, Monroe S, Zhang J. HCFA's racial and ethnic data. Health Care Financ Rev. 2000; 21(4):107-116.
17. Liang KY, Zeger SL. Longitudinal data analysis using generalized linear models. Biometrika. 1986;73 (1):13-22. doi:10.2307/2336267.
18. Zaslavsky AM, Epstein AM. How patients' socio-demographic characteristics affect comparisons of competing health plans in California on HEDIS quality measures. Int J Qual Health Care. 2005;17(1): 67-74.
19. Groessl EJ, Ganiats TG, Sarkin AJ. Sociodemographic differences in quality of life in RA. Pharmacoeconomics. 2006;24(2):109-121.
20. Bruce B, Fries JF, Murtagh KN. Health status disparities in ethnic minority patients with rheumatoid arthritis. J Rheumatol. 2007;34(7):1475-1479.
21. Iren UT, Walker MS, Hochman E, Brasington R. A pilot study to determine whether disability and disease activity are different in African American and Caucasian patients with rheumatoid arthritis in St Louis, Missouri, USA. J Rheumatol. 2005;32(4):602-608.
22. Brunner HI, Taylor J, Britto MT, et al. Differences in disease outcomes between medicaid and privately insured children. Arthritis Rheum. 2006;55(3): 378-384.
23. Pincus T, O'Dell JR, Kremer JM. Combination therapy with multiple disease-modifying antirheumatic drugs in rheumatoid arthritis. Ann Intern Med. 1999;131(10):768-774.
24. Pisetsky DS, St Clair EW. Progress in the treatment of rheumatoid arthritis. JAMA. 2001;286: 2787-2790.
25. Strand V, Singh JA. Improved health-related quality of life with effective disease-modifying antirheumatic drugs. Am J Manag Care. 2008;14(4):234-254.
26. Ziegler S, Huscher D, Karberg K, Krause A, Wassenberg S, Zink A. Trends in treatment and outcomes of rheumatoid arthritis in Germany 1997-2007. Ann Rheum Dis. 2010;69(10):1803-1808.
27. Tutuncu A, Reed G, Kremer J, Kavanaugh A. Do patients with older onset rheumatoid arthritis receive less aggressive treatment? Ann Rheum Dis. 2006; 65(9):1226-1229.
28. Lacaille D, Anis AH, Guh DP, Esdaile JM. Gaps in care for rheumatoid arthritis. Arthritis Rheum. 2005; 53(2):241-248.
29. Sokka T, Toloza S, Cutolo M, et al; QUEST-RA Group. Women, men, and rheumatoid arthritis. Arthritis Res Ther. 2009;11(1):R7.
30. Brown AF, Ang A, Pebley AR. The relationship between neighborhood characteristics and self-rated health for adults with chronic conditions. Am J Public Health. 2007;97(5):926-932.
31. Trupin L, Tonner MC, Yazdany J, et al. The role of neighborhood and individual socioeconomic status in outcomes of systemic lupus erythematosus. J Rheumatol. 2008;35(9):1782-1788.
32. Zuckerman S, Waidmann T, Berenson R, Hadley J. Clarifying sources of geographic differences in Medicare spending. N Engl J Med. 2010;363(1):54-62.
33. Song Y, Skinner J, Bynum J, Sutherland J, Wennberg JE, Fisher ES. Regional variations in diagnostic practices. N Engl J Med. 2010;363(1):45-53.
34. Keenan PS, Cleary PD, O'Malley AJ, Landon BE, Zaborski L, Zaslavsky AM. Geographic area variations in the Medicare health plan era. Med Care. 2010; 48(3):260-266.
35. Schneider EC, Zaslavsky AM, Epstein AM. Quality of care in for-profit and not-for-profit health plans enrolling Medicare beneficiaries. Am J Med. 2005; 118(12):1392-1400.
36. Baker LC, Hopkins DS. The contribution of health plans and provider organizations to variations in measured plan quality. Int J Qual Health Care. 2010; 22(3):210-218.
37. Gabriel SE. The sensitivity and specificity of computerized databases for the diagnosis of rheumatoid arthritis. Arthritis Rheum. 1994;37(6):821-823.
38. Polinski JM, Mohr PE, Johnson L. Impact of Medicare Part D on access to and cost sharing for specialty biologic medications for beneficiaries with rheumatoid arthritis. Arthritis Rheum. 2009;61 (6):745-754.
39. Gleason PP, Starner CI, Gunderson BW, Schafer JA, Sarran HS. Association of prescription abandonment with cost share for high-cost specialty pharmacy medications. J Manag Care Pharm. 2009; 15(8):648-658.